The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models
Nature Communications- United Kingdom
doi 10.1038/s41467-019-11496-z
Full Text
Abstract
Available in
Date
August 9, 2019
Authors
Publisher
Springer Science and Business Media LLC